Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate.
Open Access
- 1 March 1985
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 44 (3) , 194-198
- https://doi.org/10.1136/ard.44.3.194
Abstract
The place of sulphasalazine in the management of rheumatoid arthritis over prolonged periods of time has been compared and contrasted with that of sodium aurothiomalate. One hundred and forty-three patients (59 on sulphasalazine, 84 on sodium aurothiomalate) have been treated for periods of up to 42 months. Sulphasalazine is highly effective for some patients, though probably less frequently than sodium aurothiomalate. However, its safety profile is far superior, and very long-term treatment with sulphasalazine is a safe option for treatment of rheumatoid arthritis.This publication has 9 references indexed in Scilit:
- Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.BMJ, 1983
- Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.BMJ, 1983
- A BIOCHEMICAL ASSESSMENT OF SULPHASALAZINE IN RHEUMATOID-ARTHRITIS1982
- Preliminary criteria for clinical remission in rheumatoid arthritisArthritis & Rheumatism, 1981
- Sulphasalazine in rheumatoid arthritis.BMJ, 1980
- Salazopyrin in rheumatoid arthritisInflammation Research, 1978
- Benefits of Hospitalization in Rheumatoid ArthritisQJM: An International Journal of Medicine, 1974
- Benefits of hospitalization in rheumatoid arthritis.1974
- Course and Prognosis in Rheumatoid ArthritisAnnals of the Rheumatic Diseases, 1964